ReviewPloS one2020

Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.

James Crespo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.